Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Part of paid clinical trials in Bessemer, Alabama.
- Sponsor
- Gan and Lee Pharmaceuticals, USA
- Study ID
- NCT06737042
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Obesity and Overweight
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- GZR18 — DRUGGLP-1
- Tirzepatide — DRUGActive Comparator
Study Details
This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
Key Dates
- Start date
- Feb 12, 2025
- Status verified
- Dec 2024
- Primary completion
- Feb 9, 2026
- Completion
- Jun 22, 2026
Study Design
- Enrollment
- 285 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 24 mg GZR18 group24 mg GZR18 group: 76 participants (57 receiving GZR18 and 19 receiving placebo)
- Experimental: 36 mg GZR18 group36 mg GZR18 group: 76 participants (57 receiving GZR18 and 19 receiving placebo)
- Experimental: 48 mg GZR18 group48 mg GZR18 group: 76 participants (57 receiving GZR18 and 19 receiving placebo)
- Active Comparator: Tirzepatide groupTirzepatide group: 57 participants receiving 15 mg tirzepatide
Primary Outcome Measure
Primary Objective [ Time Frame: 36 weeks ]
Central Contacts
- Kimberly Lazaroff+888-288-5395
Locations (20)
Find similar trials in Bessemer, AL
By research site
KUR Research - Trinity @ Bessemer, AL· Bessemer, ALKUR Research - Trinity @ Centreville· Centreville, ALERG - Woodland Int'l Research Group· Little Rock, ARERG - Woodland Research Northwest· Rogers, ARArk Clinical Research Ark-Fountain Valley· Fountain Valley, CAArk Clinical Research Ark-Long Beach· Long Beach, CA
Related Studies
- BrainWeighve App Feasibility StudyRecruiting · University of California, Los Angeles · Los Angeles, California
- Effect of Watermelon on Gut and Cardiometabolic HealthRecruiting · Florida State University · Tallahassee, Florida
- CHIME: Comparing Health Interventions for Maternal EquityRecruiting · Stanford University · Palo Alto, California
- Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or ObesePHASE2 · Not Yet Recruiting · Biomed Industries, Inc. · Los Angeles, California